tyrphostin ag 1024 and imatinib mesylate

tyrphostin ag 1024 has been researched along with imatinib mesylate in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bonnet, ML; Bourhis, J; Deutsch, E; Frascogna, V; Khanfir, K; Maggiorella, L; Turhan, AG; Wen, B1

Other Studies

1 other study(ies) available for tyrphostin ag 1024 and imatinib mesylate

ArticleYear
Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.
    British journal of cancer, 2004, Nov-01, Volume: 91, Issue:9

    Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; DNA-Activated Protein Kinase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Erythroblastic, Acute; Mice; Mice, Nude; Neoplasm Recurrence, Local; Nuclear Proteins; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Tumor Cells, Cultured; Tyrphostins

2004